Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FDMT vs CGON: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGON Captures Overall Composite Edge (45.0 HOLD vs 51.3 HOLD), While FDMT Leads 3–2 on Growth & Valuation Pillars

CGON Overall Winner 6-Pillar Tally: FDMT 3 – 2 CGON (1 Tie) Matrix Metrics: FDMT 3 – 5 CGON

As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (45.0/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality, Options & Positioning), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus CGON at $84.94 (N/M Forward P/E, -4293.5% operating margin).

  • Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -222.7% operating margin) and revenue trajectory (-3.7% vs. +4505.6% YoY).
  • Technical & Structure Timing Caution: FDMT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9); meanwhile CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FDMT vs CGON
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $12.10 · SMA50: $13.07
CGON NASDAQ Head-to-Head Winner
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.17% 1D
Market Cap $6.3B
TTM Revenue $6.2M
Forward P/E N/M
Beta / 30D Vol 0.75β · 89% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 15.0 Fund 44.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 72
RSI-14: 71.7 · SMA20: $67.45 · SMA50: $68.25

6-Pillar Scorecard Institutional Category Breakdown (FDMT 3 – 2 CGON)

Columns: Metric · FDMT · CGON
1. Valuation Multiples FDMT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.6x N/M
2. Growth & Scale FDMT
Revenue Growth (YoY) +4505.6% -3.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $96M $6.2M
Market Cap $669.3M $6.3B
3. Profitability & Quality CGON
Gross Margin N/A N/A
Operating Margin -222.7% -4293.5%
Net Profit Margin -208.6% 0.0%
Return on Equity (ROE) -56.7% -28.3%
4. Balance Sheet & Cash Flow FDMT
Cash Generation (TTM) -$156M -$189M
Cash Flow Margin N/A N/A
Net Cash / Leverage $31M Net Cash $19M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CGON
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 82.4% (10th %ile) 238.6% (85th %ile)
Put/Call OI Skew 5.16x (Put-Skewed) 0.35x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FDMT (3) vs CGON (5)
Institutional Metric FDMT CGON Criterion Row Edge
Market Capitalization
Scale
$669.3M $6.3B Larger Scale CGON
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+4505.6% -3.7% Higher Growth FDMT
Operating Margin (TTM)
Profitability
-222.7% -4293.5% Higher Margin FDMT
Net Profit Margin
Profitability
-208.6% 0.0% Higher Margin CGON
Return on Equity (ROE)
Capital Efficiency
-56.7% -28.3% Higher ROE CGON
52-Week Range Position
Momentum
47% ($7–$17) 84% ($37–$94) Stronger Trend CGON
Beta / 30D Volatility
Risk Regime
1.89β · 90% Vol 0.75β · 89% Vol Lower Realized Risk CGON
Unified Institutional Score
Composite Signal
51.3 / 100 (HOLD) 45.0 / 100 (HOLD) Higher Composite FDMT
Trailing 12M Revenue (USD)
Operating Scale
$96M $6.2M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$156M ($31M Net Cash) -$189M ($19M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGON +45.97 pp
FDMT: -4.04% · CGON: +41.93%
3M Horizon CGON +32.2 pp
FDMT: -20.86% · CGON: +11.34%
6M Horizon FDMT +4.29 pp
FDMT: +39.27% · CGON: +34.98%
1Y Horizon CGON +111.63 pp
FDMT: +13.33% · CGON: +124.96%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period FDMT Revenue CGON Revenue FDMT Op. Margin CGON Op. Margin Margin Leader
FY2019 $10M N/A -729.4% N/A FDMT
FY2020 $10M N/A -424.0% N/A FDMT
FY2021 $20M N/A -395.5% N/A FDMT
FY2022 $0M N/A -3516.5% N/A FDMT
FY2023 $20M $0M -544.6% -27180.9% FDMT
FY2024 $0M $0M -507678.4% -10067.3% CGON
FY2025 $90M $0M -187.2% -4722.1% FDMT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGON CONSOLIDATION
62d in phase · OBV ACCUMULATION
Current IV 238.6%
IV Percentile 85th %ile
Put/Call OI Skew 0.35x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CGON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CGON Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.3B market capitalization and -4293.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FDMT vs CGON Key Questions & Quantitative Answers

As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (45.0/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality, Options & Positioning), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus CGON at $84.94 (N/M Forward P/E, -4293.5% operating margin). Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -222.7% operating margin) and revenue trajectory (-3.7% vs. +4505.6% YoY). Technical & Structure Timing Caution: FDMT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9); meanwhile CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with CGON at -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), FDMT cumulative revenue shifted +800.0% while CGON shifted N/A. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CGON.

FDMT screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus CGON (-28.3% ROE) capital efficiency.

In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 89% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.